Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

Aim: The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory multiple m...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Winfried Alsdorf, Joris Diels, Francesca Ghilotti, Joao Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Format:	Artigo
Sprog:	Inglês
Udgivet:	Becaris Publishing Limited 2024-08-01
Serier:	Journal of Comparative Effectiveness Research
Fag:	cartitude-4 carvykti ciltacabtagene autoleucel indirect comparison lenalidomide-refractory relapsed or refractory multiple myeloma
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!